Vancomycin Resistant Staphylococcus Aureus Infection (VRSA) Market: Evolving Market Trends & Dynamics 2024 Date: 03-01-2017 12:10 AM CET Category: Health & Medicine Press release from: Transparency Market Research - Pharmaceutical
Global Vancomycin Resistant Staphylococcus Aureus Infection (VRSA) Market: Brief Description Staphylococcus aureus is an anaerobic gram positive bacteria, commonly found in the respiratory tract of human and on the skin. This strain of bacteria is always not pathogenic but remains a major cause for respiratory diseases, skin infections and food poisoning. S.aureus strains often promote infections by producing harmful protein toxins. It is anticipated that approximately 20% of the population carries S.aureus in the anterior part of nasal passages and in the skin flora. Among all the strains of staphylococcus, S.aureus is one of the most common species that cause Staph infection and cause range of illness such as impetigo, boils, pimples, skin infections, abscesses and other life threatening diseases such as meningitis, pneumonia, sepsis, osteomyelitis and others. S.aureus infection remains one of the most common causes of postsurgical wound infection and nosocomial infections. Penicillin is the most common choice witnessed for the treatment of S.aureus infection but development of resistance from penicillin is commonly seen hence, a combination therapy along with gentamicin is prescribed for the treatment of infections. In addition, currently some of the strains have developed resistance to B-Lactam antibiotics which are termed as Methicillin resistant S.aureus (MRSA). This type of infection is growing at a rapid rate and is most often found in hospitals, clinics and in community regions. Browse Global Strategic Business Report: www.transparencymarketresearch.com/vancomycin-resistant-s... Likewise, vancomycin resistant Staphylococcus aureus refers to the strains of S.aureus that have become resistant antibiotic glycopeptides (vancomycin). Presently three classes of vancomycin-resistant S.aureus (VRSA) have emerged namely high level VRSA, vancomycin-intermediate S.aureus (VISA) and heterogenus VISA (hVISA). VISA infection was firstly identified in Japanese hospitals however, later this strain of bacteria is also found in the Asian region. Linezolid, Ceftobiprole, daptomycin, tigercycline and others are the major drugs prescribed for the treatment of VISA infection. VRSA infection usually reported in people having weakened immune system or to those who are taking vancomycin for a longer duration. The infection is also seen in those people who have undergone surgical procedures.
Seite 1 / 3